The prognostic values of prognostic nutritional index in extensive-stage small-cell lung cancer

Abstract

We aimed to assess the prognostic and predictive significance of pretreatment Prognostic Nutritional Index (PNI) in extensive-stage small-cell lung cancer (ES-SCLC) patients treated with first-line chemotherapy. We designed this study to evaluate the prognostic role of PNI in 147 ES-SCLC patients treated with platinum-based combination regimen between 2011 and 2018. Kaplan-Meier survival analyses and Cox proportional hazard models were used to examine the effects of basal PNI on overall survival (OS). The median age of the patients was 61 (range 38-81). The cutoff value for PNI was determined for whole group and patients were dichotomized into high (≥49.17) and low (<49.17). Seventy-eight (53.1%) patients had low PNI score and 69 (46.9%) patients had high PNI score. Patients with the high PNI score had better OS than those with low PNI (13 versus 12 months, respectively, and P = 0.03). The relationship between PNI score and OS was more prominent in patients over 65 years of age (13 versus 10 months, respectively, and P = 0.03). Progressionfree survival of patients with complete response to first-line treatment was statistically significantly better than the other patients (8 versus 7 months, respectively, and P = 0.02). Similarly, OS was statistically significantly better than the other patients (15 versus 8 months, respectively, and P = 0.001). The results of our study show that PNI score is useful in evaluating the OS of patients with ES-SCLC. PNI is a cost-effective prognostic marker and should therefore be included in routine clinical practice. Anti-Cancer Drugs 33: e534-e540

Predictive value of pre-operative prognostic nutritional index and systemic immune-inflammation index for efficacy and survival in patients with non-small cell lung cancer undergoing neoadjuvant chemotherapy

“…A prior retrospective study showed that low PNI (≤46) was an independent risk factor for poor OS in NSCLC patients [43]. Another study reported that patients with high PNI (≥49.17) had a longer OS than those with low PNI (<49.17) (13 months vs. 12 months, P=0.03) [44]. A study involving 157 NSCLC patients observed the impact of preoperative SII on prognosis.…”

Prognosis value of circulating tumor cell PD‑L1 and baseline characteristics in patients with NSCLC treated with immune checkpoint inhibitors plus platinum‑containing drugs

“…A previous meta-analysis demonstrated that patients with high PNI prior to treatment exhibited a longer OS, disease-free survival/relapse-free survival and PFS ( 21 ). In addition, a previous study revealed that PNI exhibited potential in predicting the OS of patients with extended-stage SCLC following first-line treatment ( 22 ). Tumor shrinkage is a relatively common prognostic indicator in chemotherapy, but it is not often used in the context of novel treatment options, such as immunotherapy.…”

Combined preoperative prognostic nutritional index and D-dimer score predicts outcome in colorectal cancer

“…It is well established that the outcome of cancer patients is determined by many factors, including nutrition status [ 5 ] and anticancer immunity [ 6 ], in addition to the cancer cells themselves; accordingly, it is plausible that prognostic markers could be more reasonable if these factors are comprehensively considered. The prognostic nutritional index (PNI), which is a marker calculated based on serum albumin and lymphocytes, is a robust prognostic indicator in many malignancies, including lung cancer [ 7 ], nasopharyngeal cancer [ 8 ], liver cancer [ 9 ], breast cancer [ 10 ], gastric cancer [ 11 ] and CRC [ 12 , 13 ]. Interestingly, previous studies have indicated that the prognostic efficacy of PNI was superior to that of other inflammation-based prognostic indicators [ 14 , 15 ].…”